Genetic Research Company, Integrated DNA Technologies, Announces Extension of CRISPR Product Line with Fresh Developments
Integrated DNA Technologies (IDT), a global leader in genomics, has announced significant additions to its end-to-end CRISPR portfolio. These innovations aim to speed up the transition from CRISPR discovery research to clinical translation, enabling researchers to develop CRISPR-based therapies more efficiently and with greater precision [1][5].
The new offerings include high-purity chemically synthesized guide RNAs (gRNAs) available in multiple modification and purity options. These reagents are ideal for translational applications such as gene editing in primary cells, which require stringent quality standards [1]. Additionally, IDT plans to launch the Alt-R HDR Enhancer Protein later in 2025, which will support enhanced homology-directed repair, thereby improving gene editing outcomes [5].
Off-target analysis services, a crucial aspect of ensuring safety and specificity in clinical contexts, are also part of the expanded portfolio. These services help scientists understand off-target edits and assess their impact [1].
IDT's VP/GM, Gene Writing & Editing, Sandy Ottensmann, stated that IDT's rich history, deep expertise, and ability to manufacture bespoke products at the highest quality uniquely positions them to innovate on their CRISPR portfolio and support customers at every stage of their gene editing journey [2].
IDT's chemically synthesized gRNAs are now available for online ordering in a range of modification and purity options, including high-performance liquid chromatography (HPLC)-purified gRNAs [1]. Future IDT launches, planned for late 2025, include the Alt-R HDR Enhancer Protein, a novel Cas9 mRNA, and a new design tool for efficient ordering of custom, configured CRISPR libraries [5].
It is important to note that the performance characteristics of IDT's products have not been established [1]. IDT products are for research use only and are not intended for use in diagnostic procedures. The purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations [1].
IDT's products manufactured under ICHQ7 are for development and investigational use only, not for use as final drug product [1]. The company's latest innovations have already supported milestone achievements such as the manufacture of the world’s first personalized CRISPR gene-editing therapy for an infant with urea cycle disorder, produced in collaboration with Aldevron [1][2][5].
IDT's vision is to enable researchers to rapidly move from the lab to life-changing advances [3]. For media inquiries, IDT can be contacted at [email protected] or 800-328-2661 (USA & Canada) or 1 319-626-8400 (outside USA) [4].
References: [1] IDT Press Release: IDT Expands CRISPR Portfolio to Accelerate Transition from Research to Clinical Translation (link) [2] IDT and Aldevron Collaborate on Personalized CRISPR Gene-Editing Therapy for Urea Cycle Disorder (link) [3] IDT's Mission and Vision (link) [4] IDT Media Contacts (link) [5] IDT Press Release: IDT Announces New CRISPR Solutions to Accelerate Development of Gene Editing Therapies (link)
- The new CRISPR portfolio expansion by Integrated DNA Technologies (IDT) includes high-purity chemically synthesized guide RNAs (gRNAs), which are essential for gene editing in primary cells, particularly in translational applications that require stringent quality standards.
- In addition to the chemically synthesized gRNAs, IDT plans to launch the Alt-R HDR Enhancer Protein later in 2025, intended to support enhanced homology-directed repair and improve gene editing outcomes.
- Off-target analysis services are part of IDT's expanded portfolio, helping scientists understand off-target edits and assess their impact, a crucial aspect of ensuring safety and specificity in clinical contexts.
